Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index‐10 (FHNSI‐10)

Patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) experience vast disease and treatment burdens. Brief, focused instruments are needed to assess patient‐reported priority symptoms and concerns as targeted outcome assessments for use in clinical research. Although the instrument was developed based on expert and patient input and is psychometrically valid, the Functional Assessment of Cancer Therapy (FACT)/National Comprehensive Cancer Network (NCCN) Head and Neck Symptom Index‐10 (FHNSI‐10) has yet to undergo content validation from the perspective of R/M SCCHN patients to evaluate its use as a brief symptom‐focused targeted endpoint assessment for use in clinical research.

• Publication year

  2021

• Venue

  Health Science Reports

• Publication date

  2021-10-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hsr2.401PMID 34708159PMCID 8525466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index‐10 (FHNSI‐10)

  2021cited by this paper
• Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index

  2020cited by this paper
• Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG‐ACRIN Cancer Research Group (E1302)

  2020cited by this paper
• Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck

  2019cited by this paper
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

  2019cited by this paper
• Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials

  2019cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.

  2017cited by this paper
• Immunotherapy in head and neck cancer: aiming at EXTREME precision

  2017cited by this paper
• Global Epidemiology of Head and Neck Cancers: A Continuing Challenge

  2016cited by this paper
• Content Validation of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale in Moderately to Highly Active Rheumatoid Arthritis

  2016cited by this paper
• A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment.

  2015cited by this paper
• The symptom burden of treatment‐naive patients with head and neck cancer

  2015cited by this paper
• Advances in the management of squamous cell carcinoma of the head and neck

  2014cited by this paper
• Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign.

  2014cited by this paper
• Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials.

  2014cited by this paper
• Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

  2013cited by this paper
• Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.

  2013cited by this paper
• Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review.

  2013cited by this paper
• To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer.

  2013cited by this paper
• Head and Neck Cancers, Version 2.2013

  2013cited by this paper
• Predictors of emotional distress in patients with head and neck cancer

  2012cited by this paper
• HEALTH and HUMAN SERVICES

  2010cited by this paper
• Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.

  2009cited by this paper
• Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

  2008cited by this paper
• Naturalistic inquiry and the saturation concept: a research note

  2008cited by this paper
• Head and neck cancer: changing epidemiology, diagnosis, and treatment.

  2008influential reference
• Quality of life scores predict survival among patients with head and neck cancer.

  2008cited by this paper
• Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

  2008cited by this paper
• A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores

  2007cited by this paper
• How Many Interviews Are Enough?

  2006cited by this paper
• Health and Quality of Life Outcomes

  2006cited by this paper
• Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• OF HEALTH AND HUMAN SERVICES Food and Drug Administration

  2004cited by this paper
• What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)

  2003influential reference
• The addition of mood and anxiety domains to the University of Washington quality of life scale

  2002cited by this paper
• Long‐Term Quality of Life of Patients With Head and Neck Cancer

  2000cited by this paper
• Clinical-Severity Staging System for Oral Cavity Cancer

  1999cited by this paper
• Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35.

  1999cited by this paper
• The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: a study of utility and validity

  1998cited by this paper
• Quality of life and functional status measures in patients with head and neck cancer.

  1996cited by this paper
• The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity

  1996cited by this paper
• Clinical-severity staging system for oral cavity cancer: five-year survival rates.

  1996influential reference
• The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper

• From clinic to couch: a pilot study of home-use photobiomodulation for radiation-induced oral mucositis and dermatitis

  2025cites this paper
• Proposed domains of postpartum sleep: a concept elicitation study using qualitative interviews

  2025cites this paper
• Patient Perceptions on a Wearable Sensor Technology for Swallowing: A Qualitative Study with Patients with Parkinson's Disease.

  2025cites this paper
• Content validation of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (NFLymSI-18) in indolent B-cell non-Hodgkin’s lymphoma

  2024cites this paper
• Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck Cancer: The FACT-HN-RAD Patient-Reported Outcome Measure.

  2023cites this paper
• Parental self-efficacy managing a child’s medications and treatments: adaptation of a PROMIS measure

  2023cites this paper
• Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index‐10 (FHNSI‐10)

  2021cites this paper